BriaCell Therapeutics Closes $8.5 Million Offering

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 — BriaCell Therapeutics Corp., a biotechnology company focused on creating innovative immunotherapies for cancer treatment, has announced the completion of a best-efforts offering of 12,325,000 common shares. The shares were priced at $0.69 each, resulting in gross proceeds of around $8.5 million before accounting for placement agent fees and other related costs. All shares in this offering were issued by BriaCell.

The funds from this offering are intended to be utilized for general corporate purposes, working capital needs, and to further the company's business goals. ThinkEquity functioned as the sole placement agent for this transaction. The securities were issued under the company's valid shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) on January 22, 2024, and became effective on January 31, 2024. The offering was carried out through a prospectus supplement and base prospectus, both of which have been filed with the SEC and are accessible on the SEC’s website.

Additionally, this press release emphasizes that it does not serve as an offer to sell or a solicitation to buy these securities in any jurisdiction where such activities would be deemed illegal before proper registration or qualification under relevant securities laws. 

BriaCell Therapeutics Corp. is dedicated to transforming cancer care through the development of pioneering immunotherapies. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!